Mr. Olympia's peptide protocol claims need context

What did @mrolympiallc actually say?

Phil Heath, seven-time Mr. Olympia, described his daily injectable peptide routine in a conversation with Transcend HRT. His stack includes BPC-157 and TB-500 in the morning, IGF-1 before training, and tesamorelin plus ipamorelin before sleep. He also mentioned 200 milligrams of testosterone. His headline claim: this combination gives him better sleep, leaner body composition, and none of "the carpal tunnel and insulin sensitivity problems" he says he experienced with human growth hormone.

These are specific physiological claims about real compounds, not vague wellness talk. That makes them checkable. So let's check them.

Does the science back this up?

Some of it, partially. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, and its effect on visceral fat reduction is documented. Ipamorelin is a selective growth hormone secretagogue with a comparatively clean side-effect profile in early research. But the stack as described goes well beyond what peer-reviewed evidence currently supports for healthy, already-muscular adults.

BPC-157 has shown regenerative effects in rodent models (Sikiric et al., 2018, Current Pharmaceutical Design), but zero completed human RCTs exist as of 2024. TB-500, a synthetic fragment of thymosin beta-4, has similarly promising preclinical data and similarly no published human trials. IGF-1 (specifically mecasermin) is FDA-approved only for severe IGF-1 deficiency in children. Using it off-label in adults for performance carries documented risks including hypoglycemia and potential mitogenic effects. Claiming IGF-1 is something you simply "love" pre-workout glosses over a risk profile that is not trivial.

What did they get wrong (or right)?

Heath deserves credit for one accurate point: tesamorelin does appear to have a more favorable metabolic profile than exogenous HGH. A randomized trial by Falutz et al. (2010, Journal of Clinical Endocrinology and Metabolism) found tesamorelin reduced visceral adipose tissue without the insulin resistance seen with HGH. His observation about avoiding carpal tunnel is also directionally consistent with tesamorelin's selective mechanism compared to supraphysiologic HGH.

Where it goes wrong: he frames an unstudied, multi-peptide injectable stack as a solved, safe protocol. It is not. Stacking BPC-157, TB-500, IGF-1, tesamorelin, and ipamorelin simultaneously has no safety data. Describing this as a routine anyone should consider, in a telehealth marketing context, without those caveats, is a problem. The claim that he "wakes up feeling a lot leaner" after a single night is also biologically implausible as a direct peptide effect rather than sleep quality improvement.

What should you actually know?

Two of these compounds, tesamorelin and ipamorelin, are available through regulated telehealth providers as compounded peptides and have more evidence behind them than the rest of this stack. Tesamorelin in particular has Phase III trial data. But compounded versions are not the same as FDA-approved Egrifta, and patients should understand that distinction clearly.

BPC-157 and TB-500 are research compounds. They are not FDA-approved for any indication. Administering them by injection carries real infection and contamination risk when sourced outside a licensed pharmacy. IGF-1 in a performance context is firmly in the high-risk, low-evidence category for most adults. A 200mg testosterone dose may be within a therapeutic range for some patients, but "200 milligrams" without specifying ester, injection frequency, or clinical indication is incomplete information that should not be taken as a personal recommendation.

If you are interested in peptide therapy, the conversation belongs with a licensed physician who can review your labs, not a social media protocol from a bodybuilding legend.